Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED.

Current urology reports·2020
Same author

Reply by Authors.

The Journal of urology·2020
Same author

Rural vs. urban disparities in association with lower urinary tract symptoms and benign prostatic hyperplasia in ageing men, NHANES 2001-2008.

International journal of clinical practice·2015
Same author

Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors.

Drugs & aging·2014
Same author

PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH.

Current bladder dysfunction reports·2013
Same author

Outcomes of lateral retroperitoneal reservoir placement of three-piece penile prosthesis in patients following radical prostatectomy.

International journal of impotence research·2010
Same journal

Focal therapy for localized prostate cancer: not all that glitters is gold.

Prostate cancer and prostatic diseases·2026
Same journal

A nationwide histopathology study reflecting the impact of the introduction of MRI in the diagnostic trajectory of prostate cancer in routine clinical care.

Prostate cancer and prostatic diseases·2026
Same journal

En-bloc vs lobe-by-lobe laser prostatectomy: where do we stand?

Prostate cancer and prostatic diseases·2026
Same journal

Response to de Riese et al. regarding "methodological and clinical considerations of MRI-based prostate cancer risk calculators".

Prostate cancer and prostatic diseases·2026
Same journal

Methodological and clinical considerations of MRI-based prostate cancer risk calculators.

Prostate cancer and prostatic diseases·2026
Same journal

Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.

Prostate cancer and prostatic diseases·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

Urethroplasty with Pedicled Tunica Vaginalis for the Treatment of Long-segment Anterior Urethral Stricture Caused by Lichen Sclerosus of Glans Penis
03:55

Urethroplasty with Pedicled Tunica Vaginalis for the Treatment of Long-segment Anterior Urethral Stricture Caused by Lichen Sclerosus of Glans Penis

Published on: October 18, 2024

PDE5 inhibitors for LUTS.

S Mouli1, K T McVary

  • 1Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

Prostate Cancer and Prostatic Diseases
|August 19, 2009
PubMed
Summary
This summary is machine-generated.

Lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are linked. Phosphodiesterase-5 (PDE5) inhibitors demonstrate effectiveness in treating LUTS, offering a promising therapeutic option.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Experiment Videos

Last Updated: Jun 20, 2026

Urethroplasty with Pedicled Tunica Vaginalis for the Treatment of Long-segment Anterior Urethral Stricture Caused by Lichen Sclerosus of Glans Penis
03:55

Urethroplasty with Pedicled Tunica Vaginalis for the Treatment of Long-segment Anterior Urethral Stricture Caused by Lichen Sclerosus of Glans Penis

Published on: October 18, 2024

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Area of Science:

  • Urology
  • Andrology
  • Pharmacology

Background:

  • Lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) frequently coexist in aging men.
  • The pathophysiological mechanisms linking LUTS and ED are complex and multifactorial.
  • Epidemiological studies suggest a potential causal relationship between these conditions.

Purpose of the Study:

  • To review the current literature on the relationship between LUTS and ED.
  • To evaluate the efficacy of phosphodiesterase-5 (PDE5) inhibitors in managing LUTS.
  • To explore the underlying mechanisms connecting LUTS and ED.

Main Methods:

  • Systematic review of published literature from 1990-2009.
  • Focus on Level 1 clinical trials investigating PDE5 inhibitors for LUTS.
  • Literature search using terms including LUTS, ED, phosphodiesterase inhibitors, and related mechanisms.

Main Results:

  • Epidemiological data indicate a probable causal link between LUTS and ED.
  • Four distinct pathophysiological mechanisms are proposed to explain the LUTS-ED association.
  • Clinical trials show significant improvement in LUTS following PDE5 inhibitor treatment.

Conclusions:

  • PDE5 inhibitors represent a promising therapeutic avenue for LUTS.
  • These agents may be used as primary treatment or adjunct therapy for LUTS.
  • Further research into the LUTS-ED relationship and PDE5 inhibitor mechanisms is warranted.